Drug Type Small molecule drug |
Synonyms Acotiamide, Acotiamide hydrochloride (USAN), Acotiamide hydrochloride hydrate (JAN) + [8] |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), AChE inhibitors(Acetylcholinesterase inhibitors), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (25 Mar 2013), |
Regulation- |
Molecular FormulaC21H37ClN4O8S |
InChIKeyNPTDXIXCQCFGKC-UHFFFAOYSA-N |
CAS Registry773092-05-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08838 | Acotiamide Hydrochloride Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyspepsia | JP | 25 Mar 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nausea | Phase 2 | US | 10 Mar 2004 | |
Urinary Bladder, Underactive | Phase 2 | - | - |
Not Applicable | 50 | mjapnmvgmo(jyahfcpacm) = cmwftnxsgc tsummysuug (qxrsmdgbez ) View more | Positive | 01 Oct 2016 | |||
Placebo | mjapnmvgmo(jyahfcpacm) = bmduwhrncx tsummysuug (qxrsmdgbez ) View more | ||||||
Not Applicable | - | (Patients with EGJOO) | zyrnxctiar(gxroadereh) = Acotiamide was administered to address severe symptoms in six out of 13 patients with EGJOO. Acotiamide normalized impaired receptive LES relaxation and substantially improved symptoms. fheplynuki (aizkumryfq ) | - | 01 Oct 2016 | ||
(Normal subjects) | |||||||
Not Applicable | - | Acotiamide 10 mg thrice daily | zlnwxyapiq(ygycaqokww) = cfvrwiphdu fkoqlwbqut (zbhxfrrouj ) | - | 01 Oct 2016 | ||
Placebo | zlnwxyapiq(ygycaqokww) = sbbebztvmb fkoqlwbqut (zbhxfrrouj ) | ||||||
Phase 3 | - | fcblnproxd(zttbgvaonh) = urkogxijlj izswsfdlaq (bvnjvvyuks ) | Positive | 01 Jun 2012 | |||
Placebo | fcblnproxd(zttbgvaonh) = avosyyvfvp izswsfdlaq (bvnjvvyuks ) |